Benitec Biopharma Inc.

Benitec Biopharma Inc.

Company snapshot

• Legal name: Benitec Biopharma Inc. (Delaware corporation); predecessor Benitec Limited (Australia).
• Headquarters: Hayward, California; principal office at 3940 Trust Way, Hayward, CA 94545.
• Nasdaq ticker: BNTC.
• Focus: Clinical-stage biotechnology company developing genetic medicines using a ddRNAi-based “silence and replace” approach. Lead program BB-301 targets oculopharyngeal muscular dystrophy (OPMD).
• Business model: No current product sales; no established sales, marketing, or distribution operations. The company expects to fund operations through equity or debt financing, collaborations, and grants.

Core technology and lead program

• Platform: A silence-and-replace approach that combines permanent gene silencing via ddRNAi with simultaneous expression of a functional transgene, delivered using adeno-associated virus (AAV) vectors. The platform is designed to provide a long-lasting therapeutic effect from a single administration.
• BB-301 (lead therapy for OPMD):
  • AAV9-based gene therapy intended to permanently silence the mutant PABPN1 gene using two shmiR sequences from a single DNA construct.
  • Simultaneously expresses a codon-optimized, RNAi-resistant wild-type PABPN1 transgene to restore normal cellular function.
  • Uses a muscle-specific promoter (Spc5-12) for targeted expression.
  • Designed for delivery to pharyngeal muscle via an intraoperative method using a proprietary injection needle and multi-injection devices.
• Regulatory status: BB-301 has U.S. orphan drug designation and fast-track designation, and EU orphan designation. An IND was cleared by the FDA in June 2023, and the first subject was treated in the Phase 1b/2a trial in November 2023. Cohort 1 completed 12-month post-treatment follow-up; three subjects had been treated in Cohort 2 as of the report.

Product pipeline and intellectual property

• Pipeline focus: BB-301 for OPMD based on the silence-and-replace approach.
• Intellectual property:
  • Four active OPMD-related patent families covering shRNA/shmiR constructs targeting PABPN1 (including BB-301 components), the silence-and-replace construct, delivery strategies for OPMD treatment, and intraoperative delivery devices and injections for pharyngeal muscle.
  • A separate patent family covering an AAV vector with a modified phospholipase A2 (PLA2) domain used for BB-301 delivery.
  • Know-how related to target selection, ddRNAi design, and delivery methods.
  • One OPMD patent family (family #3) was passively abandoned and is no longer active for the OPMD program.
• The company protects its technology through patents, trade secrets, and know-how.

Manufacturing and commercialization

• Manufacturing model: No owned manufacturing facilities; the company uses third-party contract manufacturers and suppliers.
• Regulatory pathway: In the U.S., gene therapy products are regulated as biologics; development typically requires IND clearance, a BLA submission for approval, and facility inspections for cGMP compliance.
• Commercialization strategy: No current commercial operations; the company intends to partner with larger organizations for development, regulatory activity, and distribution as programs advance.

Financial position and resources (as of June 30, 2026)

• Cash and cash equivalents: $180.0 million.
• Accumulated losses: $273.7 million.
• Revenue: None to date; the company has not generated revenue from product sales.
• The company reports ongoing operating losses and does not expect product revenue in the near term.
• Expenses are expected to increase with continued preclinical and clinical development; funding sources include equity or debt financings, collaborations, and grants.
• Liquidity: The company indicates its cash runway supports at least the next 12 months from the filing date and acknowledges the need for additional funding to continue operations and development.

Human capital and facilities

• Employees: 24 full-time employees as of June 30, 2026. Educational breakdown includes one MD/PhD, eight PhDs, four master’s degrees, two biotechnology certificates, and one MBA (13 employees with postgraduate degrees).
• Locations and facilities:
  • Hayward, California: corporate headquarters and R&D facility (~7,295 sq. ft.), lease expiring December 2027.
  • Los Angeles, California: additional office space with lease expiring January 2028.
• Management considers current facilities suitable for anticipated needs.

Market context

• The company has not begun commercial sales.
• No approved therapies currently exist for OPMD. BB-301 is in early clinical development and has orphan-designated status. The company has discussed a potential market opportunity exceeding $1 billion over the product’s commercial life if BB-301 gains approval.